 Iovance Biotherapeutics Inc NASDAQ: IOVA has announced clinical data for its tumor-infiltrating lymphocyte TIL therapy LN-145 in patients with metastatic non-small cell lung cancer mNSCLC. The cohort enrolled patients that had progressed on prior immune checkpoint inhibitor ICI therapy, including patients with oncogene-driven tumors who received prior tyrosine kinase inhibitor therapy. 